Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment

PINTology: A short history of the lncRNA LINC-PINT in different diseases

LINC-PINT is a p53-induced long intergenic noncoding transcript that plays a crucial role in many diseases, especially cancer. This long noncoding RNA (lncRNA) gene produces in total 102 (LNCipedia) alternatively spliced variants (LINC-PINT:1 to LINC-PINT:102). The functions of known variants include RNA transcripts, host transcripts for circular RNA (circRNA) generation and as sources for the translation of short peptides. In most human tumors, LINC-PINT is down-regulated where it serves as a tumor suppressor. However, the diversity of its functions in other maladies signifies its general clinical importance. Current LINC-PINT molecular functions include RNA-protein interactions, miRNA sponging and epigenetic modulation with these mechanisms operating in different cellular contexts to exert effects on biological processes ranging from DNA damage responses, cell cycle and growth arrest, senescence, cell migration and invasion, and apoptosis. Genetic polymorphisms in LINC-PINT have also been functionally associated with cancer and other pathologies including the autoimmune diseases pemphigus foliaceus and arthritis. Hence, LINC-PINT shows great potential as a clinical biomarker, especially for the diagnosis and prognosis of cancer. In this review, we explore the current knowledge highlighting the distinctive molecular functions of LINC-PINT in specific cancers and other disease states. This article is categorized under: RNA in Disease and Development > RNA in Disease.

Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy

Background

There are no useful biomarkers for the clinical outcome of advanced esophageal squamous cell carcinoma (ESCC). In this study, we aimed to investigate the prognostic value of soluble PD-L1 (sPD-L1) in serum of patients with locally advanced or metastatic ESCC who received cytotoxic chemotherapy as first-line treatment.

Materials and Methods

This study evaluated the expression pattern of PD-L1 by immunohistochemistry and sPD-L1 concentration, and correlation with clinicopathological factors and overall survival (OS) in 190 patients with ESCC.

Results

sPD-L1 concentration was highly expressed in ESCC, especially in female patients. Patients with a high sPD-L1 level (≥0.63 ng/mL) had a shorter OS than those with a low sPD-L1 level (<0.63 ng/mL). In a multivariate analysis, high sPD-L1 concentration remained an independent prognostic factor of OS after adjustment for possible confounders. However, tissue PD-L1 expression level was non-prognostic in this study.

Conclusion

There was no significant correlation between serum sPD-L1 concentration and tissue PD-L1 expression level. sPD-L1 concentration before treatment could be an effective and convenient biomarker of prognosis in patients with locally advanced or metastatic ESCC treated with combination cytotoxic chemotherapy.

Downregulation of lncRNA LINC-PINT Participates in the Recurrence of Esophageal Squamous Cell Carcinoma Possibly by Interacting miRNA-21

Backgrounds: LncRNA long intergenic non-protein coding RNA p53 induced transcript (LINC-PINT) is downregulated in multiple types of cancer cells. The authors explored the possible involvement of LINC-PINT in esophageal squamous cell carcinoma (ESCC). Materials and Methods: Sixty-two patients with early-stage ESCC were included in this study. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect gene expression in plasma from ESCC patients and healthy controls. Diagnostic analysis was performed by receiver operating characteristic (ROC) curve. Transfections were performed to analyze gene interactions. Cell invasion and migration were analyzed by Transwell assays. Results: Plasma LINC-PINT was downregulated and microRNA (miRNA)-21 was upregulated in early-stage ESCC patients. Diagnostic analysis by ROC curve revealed that downregulation of lncRNA LINC-PINT distinguished ESCC patients from healthy controls. Plasma levels of LINC-PINT and miRNA-21 were negatively correlated in ESCC patients. After surgical resection, only local recurrence was observed during 3-years of follow-up. LINC-PINT expression was further downregulated in recurrent patients but not in nonrecurrent patients. ROC curve analysis revealed that plasma levels of LINC-PINT at 12 months before recurrence can be used to distinguish ESCC patients from healthy controls. Overexpression of LINC-PINT could inhibit the expression of miRNA-21 in human ESCC cells, whereas LINC-PINT expression was not altered by miR-21 overexpression. Conclusion: Therefore, downregulation of LINC-PINT participated in the recurrence of ESCC possibly by interacting with miRNA-21.